Monitor for SEC filing of the resale registration statement and any updates on clinical trial progress in myasthenia gravis and Sjögren’s disease. Assess whether future capital raises are likely given current runway.
Price Chart
Executive Summary
Vor Biopharma announced a private placement of 5,338,078 shares at $14.05 per share, raising approximately $75 million in gross proceeds. The financing, led by new investor TCGX, will be used to advance clinical development of telitacicept in myasthenia gravis and primary Sjögren’s disease, among other corporate purposes.
Key Financial Metrics
Key Facts
- Vor Biopharma is conducting a private placement of 5,338,078 shares at $14.05 per share.
- Gross proceeds are expected to be approximately $75 million, before expenses.
- The financing is led by new investor TCGX; no placement agent was used.
- Proceeds will fund Phase 3 trials in myasthenia gravis and primary Sjögren’s disease, business development, and general corporate purposes.
- A registration rights agreement requires Vor Bio to file a resale registration statement with the SEC.
Financial Impact
$75 million gross proceeds from issuance of ~5.34M shares, representing ~9.5% dilution based on current market cap of $563M
Risk Factors
- Dilution to existing shareholders from issuance of new shares.
- Execution risk in clinical development of telitacicept despite promising forward-looking statements.
- Market conditions could affect timing or completion of the offering despite announced agreement.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3263720 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | Press Release | $23.37 $23.24 | ▼ −0.58% | ▲ +0.48% | $18.47 (−20.97%) |
Jul 9, 2026 12w ago | 3 | $19.14 $23.67 | ▲ +23.67% | ▲ +21.24% | $18.47 (−3.50%) |
Jun 11, 2026 16w ago | Institutional Cluster | $14.09 $19.75 | ▲ +40.17% | ▲ +38.28% | $18.47 (+31.09%) |
Jun 8, 2026 16w ago | Press Release | $13.29 $20.10 | ▲ +51.24% | ▲ +49.61% | $18.47 (+38.98%) |
May 7, 2026 21w ago | EFFECT | $16.08 $13.44 | ▼ −16.42% | ▼ −19.55% | $18.47 (+14.86%) |
Apr 27, 2026 22w ago | S-3 | $14.38 $14.10 | ▼ −1.95% | ▼ −7.42% | $18.47 (+28.44%) |
Apr 27, 2026 22w ago | DEFA14A | $14.38 $14.10 | ▼ −1.95% | ▼ −7.42% | $18.47 (+28.44%) |
Mar 27, 2026 27w ago | Press Release | $14.48 $14.12 | ▼ −2.49% | ▼ −15.23% | $18.47 (+27.56%) |
Mar 23, 2026 27w ago | Press Release | $12.15 $15.32 | ▲ +26.09% | ▲ +17.19% | $18.47 (+52.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access